Common Treatments for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also impact other systems in the body, including the skin, eyes, lungs, heart, and blood vessels.
July 1, 2024
by David Orchard-Webb
Second Biosimilar Tocilizumab Injection approved for marketing
Second Biosimilar Tocilizumab Injection approved for marketing.
January 18, 2023
by www.nmpa.com
Theramex, Enzene Biosciences Partner on Arthritis Treatment
Will develop and commercialize Tocilizumab, a biosimilar for the treatment of rheumatoid arthritis.
January 5, 2022
by contractpharma
Rheumatoid Arthritis accounts for 18.9% share of global Immunology clinical trial activity in 2020
Rheumatoid Arthritis accounted for an 18.9% share of the global clinical trials within the Immunology therapy area in 2020, registering a decrease of 4.4% when compared with the last ten-year average of 23.3% share, according to GlobalData.
June 17, 2021
by pharmaceutical-technology
NICE broadens access to treatments for rheumatoid arthritis
The National Institute for Health and Care Excellence (NICE) has published final draft guidance broadening access to several treatment for patients with moderate to severe rheumatoid arthritis.
June 16, 2021
by pharmatimes
Biogen Welcomes NICE Announcement on TA375 as a Landmark Decision for UK Patients with Moderate Rheumatoid Arthritis
Biogen UK welcomes the decision by the National Institute for Health and Care Excellence (NICE) to broaden patient access to biologics, including biosimilars, to treat moderate rheumatoid arthritis (RA).
June 11, 2021
by firstwordpharma
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).
January 22, 2021
by pharmatimes
Henlius Adalimumab Biosimilar Approved by NMPA
Shanghai Henlius Biotech, Inc. announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis ...
December 9, 2020
by prnasia
SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
SynAct Pharma AB, a clinical stage biopharmaceutical company developing novel therapies of inflammatory diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has reviewed unblinded and validated data from part 1 of the ...
November 9, 2020
by prnasia
NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Rinvoq (upadacitinib) for people with previously treated severe active rheumatoid arthritis (RA).
November 9, 2020
by pharmatimes
Gilead’s oral JAK inhibitor filgotinib wins EU approval
Gilead Science’s Galapagos-partnered oral JAK inhibitor filgotinib has been approved by the European Commission under the brand name Jyseleca for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
September 30, 2020
by pharmatimes
Gilead gets approval for Jyseleca (filgotinib) in Japan for rheumatoid arthritis
Gilead Japan will hold marketing authorisation of Jyseleca in Japan while Eisai will be responsible for product distribution.
September 27, 2020
by expresspharma